Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceIn: Nature Cancer , Jg. 6 2025, Nr. 2, S. 307 – 322DOI (Open Access)
-
Early switch from run-in with targeted to immunotherapy in advanced BRAFV⁶⁰⁰-positive melanoma : final results of the randomised phase II ImmunoCobiVem trialIn: ESMO Open , Jg. 10 2025, Nr. 5, 105053DOI (Open Access)
-
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusIn: Frontiers in Immunology , Jg. 16 2025, 1536642DOI (Open Access)
-
RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanomaIn: Clinical and Translational Medicine , Jg. 15 2025, Nr. 1, e70094DOI (Open Access)
-
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanomaIn: British Journal of Dermatology: BJD , Jg. 192 2025, Nr. 3, S. 481 – 491
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC) , Jg. 202 2024, 113976DOI (Open Access)
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) , Jg. 200 2024, 113536DOI (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 210 2024, 114295DOI (Open Access)
-
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaIn: Science Advances , Jg. 10 2024, Nr. 48, eadp4670DOI (Open Access)
-
KDM5B predicts temozolomide-resistant subclones in glioblastomaIn: iScience , Jg. 27 2024, Nr. 1, 108596DOI (Open Access)
-
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaIn: Clinical Cancer Research , Jg. 29 2023, Nr. 2, S. 488 – 500DOI (Open Access)
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC) , Jg. 191 2023, 112957
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1395DOI (Open Access)
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: eBioMedicine , Jg. 96 2023, 104774DOI (Open Access)
-
Database for queries of melanoma cohorts with molecular and clinical dataIn: Pigment Cell and Melanoma Research , Jg. 36 2023, Nr. 2, S. 252 – 258DOI (Open Access)
-
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma : The ImmunoCobiVem phase 2 randomised trialIn: European Journal of Cancer (EJC) , Jg. 190 2023, 112941
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research , Jg. 29 2023, Nr. 15, S. 2894 – 2907
-
Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytomaIn: Acta Neuropathologica , Jg. 149 2023, Nr. 4, S. 551 – 564DOI (Open Access)
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1292 – 1308DOI (Open Access)
-
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionIn: Cancers , Jg. 15 2023, Nr. 13, 3448DOI (Open Access)
-
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathyIn: Journal of the European Academy of Dermatology and Venereology , Jg. 37 2023, Nr. 5: Special issue on melanoma: Immune check point and BRAF‐MEK inhibitors in melanoma, S. 907 – 913DOI (Open Access)
-
Prognostic factors in the primary care of patients with Merkel cell carcinoma : A monocentric cohort study of 108 patients from a tertiary referral centreIn: JEADV Clinical Practice , Jg. 2 2023, Nr. 4, S. 810 – 818DOI, Online Volltext (Open Access)
-
Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed TherapiesIn: Microbiology Spectrum , Jg. 11 2023, Nr. 3, e04401-22DOI (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet , Jg. 400 2022, Nr. 10358, S. 1117 – 1129
-
BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor MicroenvironmentIn: Cancer Research , Jg. 82 2022, Nr. 2, S. 264 – 277DOI (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology , Jg. 36 2022, Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 – 44DOI (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine , Jg. 12 2022, Nr. 11, e1090DOI, Online Volltext (Open Access)
-
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 6, e004509DOI (Open Access)
-
MCU controls melanoma progression through a redox-controlled phenotype switchIn: EMBO Reports , Jg. 23 2022, Nr. 11, e54746DOI (Open Access)
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology , Jg. 36 2022, Nr. S1, S. 29 – 34DOI (Open Access)
-
Persister state-directed transitioning and vulnerability in melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Nature Communications , Jg. 13 2022, Nr. 1, S. 35 – 36DOI, Online Volltext (Open Access) -
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology , Jg. 11 2021, 725549DOI, Online Volltext (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) , Jg. 152 2021, S. 139 – 154
-
Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up : A monocentre studyIn: European Journal of Cancer (EJC) , Jg. 154 2021, S. 167 – 174
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology , Jg. 11 2021, 741993DOI, Online Volltext (Open Access)
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers , Jg. 13 2021, Nr. 10, S. 2319DOI, Online Volltext (Open Access)
-
Integrative genomic analyses of patient-matched intracranial and extracranial metastases reveal a novel brain-specific landscape of genetic variants in driver genes of malignant melanomaIn: Cancers , Jg. 13 2021, Nr. 4, S. 731DOI, Online Volltext (Open Access)
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) , Jg. 148 2021, S. 395 – 404
-
Melanoma Differentiation Trajectories Determine Sensitivity Toward Pre-Existing CD8⁺ Tumor-Infiltrating LymphocytesIn: Journal of Investigative Dermatology , Jg. 141 2021, Nr. 10, S. 2480 – 2489DOI (Open Access)
-
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibIn: Clinical Cancer Research , Jg. 27 2021, Nr. 16, S. 4500 – 4510DOI (Open Access)
-
The predictive and prognostic significance of cell-free DNA concentration in melanomaIn: Journal of the European Academy of Dermatology and Venereology , Jg. 35 2021, Nr. 2, S. 387 – 395DOI (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : A randomised, double-blind, placebo-controlled, phase 2 trialIn: Lancet , Jg. 395 2020, Nr. 10236, S. 1558 – 1568
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer (EJC) , Jg. 131 2020, S. 18 – 26
-
Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses : A prospective, randomized and rater-blinded study (ACTICAP)In: Journal of the European Academy of Dermatology and Venereology , Jg. 34 2020, Nr. 12, S. E844 – E846
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. 10, S. 1165 – 1168DOI (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist , Jg. 61 2020, Nr. 7, S. 669 – 675DOI (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe , Jg. 26 2020, Nr. 8, S. 713 – 720
-
Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free rna for noninvasive early detection of cancerIn: Cancers , Jg. 12 2020, Nr. 2, S. 353DOI, Online Volltext (Open Access)
-
S3 Guideline for the Diagnosis, Therapy and Follow‐Up of Malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. 10, S. 1079 – 1208DOI (Open Access)
-
Zelkovamycin is an OXPHOS Inhibitory Member of the Argyrin Natural Product FamilyIn: Chemistry - A European Journal , Jg. 26 2020, Nr. 39, S. 8524 – 8531DOI (Open Access)
-
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanomaIn: JCO Precision Oncology , Jg. 3 2019DOI (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC) , Jg. 119 2019, S. 66 – 76DOI (Open Access)
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer , Jg. 7 2019, Nr. 1, S. 141DOI, Online Volltext (Open Access)
-
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer (EJC) , Jg. 109 2019, S. 137 – 153
-
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma CellsIn: Journal of Investigative Dermatology , Jg. 139 2019, Nr. 12, S. 2506 – 2516.e10DOI (Open Access)
-
ctDNA as a noninvasive monitoring tool in metastatic melanomaIn: Journal of Clinical Oncology (JCO) , Jg. 37 2019, Nr. Suppl. 15, S. 9548
-
Actinic keratoses treated with cold atmospheric plasmaIn: Journal of the European Academy of Dermatology and Venereology , Jg. 32 2018, Nr. 1, S. e37 – e39
-
RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomasIn: Oncogene , Jg. 37 2018, Nr. 47, S. 6136 – 6151
-
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of MelanomaIn: Cell Reports , Jg. 21 2017, Nr. 7, S. 1953 – 1967DOI (Open Access)
-
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 83 2017, S. 142 – 145
-
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology , Jg. 43 2017, Nr. 3, S. 604 – 611
-
Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of klothoIn: Clinical Cancer Research , Jg. 23 2017, Nr. 12, S. 3181 – 3190DOI (Open Access)
-
Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study.In: JMIR mhealth and uhealth , Jg. 5 2017, Nr. 7, e101DOI (Open Access)
-
Prognostic factors and treatment outcomes in 444 patients with mucosal melanomaIn: European Journal of Cancer (EJC) , Jg. 81 2017, S. 36 – 44
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget , Jg. 8 2017, Nr. 25, S. 40683 – 40692DOI (Open Access)
-
Aetiology, comorbidities and cofactors of chronic leg ulcers : retrospective evaluation of 1 000 patients from 10 specialised dermatological wound care centers in GermanyIn: International Wound Journal (IWJ) , Jg. 13 2016, Nr. 5, S. 821 – 828
-
Arbeitsgemeinschaft Dermatologische Onkologie (ADO) : Bericht über den 3. ADO Nachwuchs-RetreatIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 14 2016, Nr. 2, S. 213 – 214
-
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer (EJC) , Jg. 67 2016, S. 66 – 72
-
Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosisIn: Medicine , Jg. 95 2016, Nr. 29, S. e4332DOI (Open Access)
-
JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral CancersIn: Cancer Research , Jg. 76 2016, Nr. 18, S. 5538 – 5549
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie (AMT) , Jg. 34 2016, Nr. 1-2, S. 14 – 22
-
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyIn: Cancer Research , Jg. 76 2016, Nr. 15, S. 4347 – 4358
-
Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012In: International Wound Journal (IWJ) , Jg. 13 2016, Nr. 5, S. 951 – 956
-
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanomaIn: European Journal of Cancer (EJC) , Jg. 59 2016, S. 109 – 112
-
Purpura fulminans related to paroxysmal nocturnal haemoglobinuriaIn: European Journal of Dermatology (EJD) , Jg. 26 2016, Nr. 4, S. 397 – 398
-
The role of Orai–STIM calcium channels in melanocytes and melanomaIn: Journal of Physiology , Jg. 594 2016, Nr. 11, S. 2825 – 2835
-
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanomaIn: Experimental Dermatology , Jg. 24 2015, Nr. 9, S. 709 – 710
-
Die multispektraloptoakustische Tomographie (MSOT) zur nichtinvasiven Diagnostik des Schildwächterlymphknotens bei Patienten mit malignem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 13 2015, Nr. 12, S. 1323
-
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imagingIn: Immunotherapy , Jg. 7 2015, Nr. 317, S. 317ra199
-
Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulationsIn: Experimental Dermatology , Jg. 24 2015, Nr. 2, S. 155 – 157DOI (Open Access)
-
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanomaIn: Oncogene , Jg. 34 2015, Nr. 23, S. 2951 – 2957
-
Tumorstammzellen im MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 13 2015, Nr. 2, S. 118 – 124
-
'TWIST and switch' metastasisIn: Pigment Cell and Melanoma Research , Jg. 27 2014, Nr. 2, S. 157 – 158
-
Arbeitsgemeinschaft Dermatologische Onkologie (ADO)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 12 2014, Nr. 1, S. 96 – 97
-
Bacterial spectrum colonizing chronic leg ulcers : a 10-year comparison from a German wound care centerIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 12 2014, Nr. 12, S. 1121 – 1127
-
Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entryIn: Pigment Cell and Melanoma Research , Jg. 27 2014, Nr. 3, S. 442 – 453
-
SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathwayIn: Journal of Investigative Dermatology , Jg. 134 2014, Nr. 4, S. 1108 – 1118
-
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.In: Cancer Medicine , Jg. 2 2013, Nr. 1, S. 76 – 85DOI (Open Access)
-
Immunotherapy responses of patients with metastatic melanoma are linked to IL-17 signalingIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1224 – 1225
-
Analysis of gender-specific Differences in Response to First-line Treatment with Immunotherapy or targeted Therapy in Melanoma Patients with metastatic Stage IV Melanoma : An ADO/DeCOG Study of 2032 Patients from the prospective, multicenter Skin Cancer Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 16 – 17
-
Correlation of Laboratory Parameters at the Start of adjuvant Treatment of Stage III Melanoma Patients with clinical Outcome : A multicenter Real World StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 8 – 9
-
Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma : Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S1235 – S1236 -
PD-L1 Expression in Lymph Node Metastases as a Predictor of adjuvant Immunotherapy Success in Stage III Melanoma Patients: An Analysis of the prospective ADOREG Study TRIM-ADJUVANTIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 15 – 16
-
RECQL4-mediated Downregulation of MHC Class II promotes Immune Evasion and reduced Anti-PD-1 Response in Melanoma PatientsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 6
-
The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 17 – 18
-
Außergewöhnlicher Therapiebenefit von Imatinib bei cKIT-mutiertem Schleimhautmelanom mit nachfolgendem KIT-Mutationsverlust
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21 – 22DOI (Open Access) -
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 – 28DOI (Open Access) -
Predicting and targeting clonally expanding, tmz-resistant tumor cells in glioblastoma
28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO); NOV 15-19, 2023; Vancouver, Canada,In: Neuro-Oncology , Jg. 25 2023, Nr. Suppl. 5, S. v110 – v110 -
Cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratosesIn: Experimental Dermatology , Jg. 31 2022, Nr. 2, S. e24 – e24
-
Compartment-based proteomics of CD8high vs. CD8low melanoma regions reveals differential regulation of TOR signaling
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 12 -
Context Sensitive Links 9 of 29 Circulating tumor derived cell-free RNA (cfRNA) as a potential biomarker in melanomaIn: Experimental Dermatology , Jg. 31 2022, Nr. 2, S. e26 – e27
-
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma : Interim analysis of the ImmunoCobiVem studyIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 16_Suppl., S. 9548
-
Epigenetisch-metabolische Vulnerabilität von medikamententoleranten Persisterzellen im MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 24
-
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 12 – 13 -
Inhibition of the mTOR inhibitory protein sirtuin 1 leads to faster tumor growth under PD1-based immune checkpoint blockadeIn: Experimental Dermatology , Jg. 31 2022, Nr. 2, S. e92
-
KDM5B's role in creating radiation synthetic vulnerabilities and its effects on sequential therapy combinations
48th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF): Virtual, Innsbruck, 23-26 February 2022,In: Experimental Dermatology , Jg. 31 2022, Nr. 2, S. e9 – e10 -
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 16 – 17 -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 3 -
Epigenetic-metabolic Vulnerability of drug-tolerant Persister Cells in MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 36
-
PTHrP-induced hypercalcemia Psychosyndrome under Immune Checkpoint Blockade in Patients with penile Squamous Cell Carcinoma
31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, Hamburg, Germany and Virtual,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 23DOI (Open Access) -
The Role of KDM5B in the Development of radiation-synthetic Vulnerability and its Effect on sequential Therapy CombinationsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 74
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 58 – 59
-
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28DOI (Open Access)
-
Apoptotische Gastritis nach Immuncheckpointblockade : Ein typisches histopathologisches MusterIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P12DOI (Open Access)
-
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06DOI (Open Access)
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36DOI (Open Access)
-
Distinct melanoma differentiation trajectories driven by MAPKi associate with activation of CD8+tumor-infiltrating lymphocytesIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV17DOI (Open Access)
-
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44DOI (Open Access)
-
Application of circulating cell-free tumor DNA (ctDNA) profiles for monitoring metastatic melanoma progression under therapy
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology , Jg. 27 2018, Nr. 3, S. e22 – e23DOI (Open Access) -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 61 – 62DOI (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 26 – 27DOI (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. Suppl. 6, S. 3
-
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 3DOI (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 11 – 12DOI (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 38DOI (Open Access) -
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 28DOI (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 15 2017, Nr. Suppl. 3, S. 26 – 27
-
Senescence-like responses in irradiated melanoma cellsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 13 2015, Nr. Suppl.2, S. 34
-
Redirecting resistance evolution in BRAFV600 melanoma by inhibition of the peroxiredoxin-thioredoxin system2025DOI (Open Access)
-
MelanomaIn: Braun-Falco's Dermatology / Plewig, Gerd; French, Lars; Ruzicka, Thomas; Kaufmann, Roland; Hertl, Michael (Hrsg.) 2022, S. 1855 – 1871
-
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 44DOI (Open Access) -
Ausgedehntes Rezidiv eines atypischen Fibroxanthoms
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 99DOI (Open Access) -
Langfristiger Therapieerfolg von sequentieller Immun- und zielgerichteter Therapie beim metastasierten malignen Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 47 – 48DOI (Open Access) -
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 – 77DOI (Open Access) -
Therapieansprechen auf Sunitinib bei Imatinib-resistentem Rezidiv eines Dermatofibrosarkoma protuberans am Capillitium
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 99 – 100DOI (Open Access) -
Therapieoption beim lokal fortgeschrittenen kutanen Plattenepithelkarzinom nach Cemiplimab-Resistenz
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 72DOI (Open Access) -
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 29 – 30 -
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 105 -
Partielle Remission auf Cemiplimab eines beidseitig Orbitae-infiltrierenden Basalzellkarzinoms des Mittelgesichts
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 44 – 45 -
Persister state-directed transitioning and vulnerability in melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 35 – 36